Tufts CSDD Analysis Finds AI Clinical Monitoring Agent Can Generate Up to $21 Million in Net Financial Value Per Drug Development Program

Medable and the Tufts Center for the Study of Drug Development (Tufts CSDD) have released an analysis quantifying the net financial value of deploying an artificial intelligence (AI) clinical monitoring agent across oncology drug development programs.¹

Using Tufts CSDD's expected net present value framework and operational data from Medable's Clinical Monitoring Agent, the analysis found expected Net Present Value (eNPV) gains of approximately $7.5 million for a Phase II trial, $11.3 million across combined Phase II and Phase III development, and $21 million for a Phase III trial.

ROI multiples came in at 64x for Phase II and 82x for Phase III clinical trials. Direct operating cost reductions in on-site monitoring were estimated at approximately $4.4 million per Phase II study and $5.6 million per Phase III study.

"To our knowledge, this is the first time that eNPV modeling based on actual use and benchmark data has been applied to quantify the net financial impact of an agentic AI solution deployed to support a drug development program," said Ken Getz, executive director of Tufts CSDD, in a press release. "The financial value created by the investment and deployment of the monitoring agent was driven by operational efficiencies such as the reduction in the number of on-site visits and reduced travel costs as well as accelerated enrollment and database lock timelines."

Timeline compression as a value driver

Beyond cost savings, the analysis found that the monitoring agent can accelerate clinical development by approximately 18 weeks. Faster patient enrollment reduced enrollment timelines by approximately 109 to 119 days, while earlier database lock shortened closeout activities by about two weeks. Those time savings translate into earlier regulatory submission and earlier realization of future revenue.

Additional analysis identified administrative off-site monitoring task efficiencies of approximately $600,000 for Phase II and $1.7 million for Phase III—savings reflecting clinical research associate time that could be reallocated to other studies, though these were not included in the eNPV calculations.

The analysis also modeled the impact at the portfolio level. For a sponsor with 20 active oncology indications, deploying the monitoring agent across Phase II and Phase III studies could generate as much as $226 million in incremental portfolio eNPV. For a sponsor with 50 active indications, that figure could reach $565 million.

Tufts CSDD and Medable plan to publish a detailed, peer-reviewed paper based on the analysis later this year.

Operational context from the field

These new findings connect to a broader conversation about what makes agentic AI operationally viable in clinical development. At the 2026 DIA Global Annual Meeting, Angie Maurer, vice president of AI-enabled clinical development at Medable, spoke with Applied Clinical Trials about the structural barriers that have historically kept automation out of reach in protocol management and why those barriers are now giving way.²

Maurer traced the shift to a convergence of three developments: large language models capable of deciphering nuanced clinical language, industry standards like the Unified Study Definition Model providing structured output, and the ability to operate within validated environments.

"Today there's a convergence of three things happening at once," she said.

The downstream implications for how trial data flows are significant. When a protocol is structured data rather than a text document, changes propagate differently.

"When you have a change in a visit window, that's no longer just a text edit," Maurer said. "That visit window change becomes a data object that has relationships to other data objects downstream."

For Maurer, that shift is also what makes the FDA's continuous oversight ambitions operationally achievable—connecting the efficiency case for agentic AI to the broader regulatory modernization trajectory the industry is navigating.

References

1. New Tufts CSDD Analysis Finds AI Agents Can Deliver Up to $21 Million in Net Financial Value Per Drug Development Program and Up to 82x ROI. News release. Medable. August 12, 2026. Accessed August 12, 2026. https://www.businesswire.com/news/home/20260812470591/en/New-Tufts-CSDD-Analysis-Finds-AI-Agents-Can-Deliver-Up-to-%2421-Million-in-Net-Financial-Value-Per-Drug-Development-Program-and-Up-to-82x-ROI
2. Applied Clinical Trials at the 2026 DIA Global Annual Meeting: Conversations on Data, Outsourcing, and the Patient Voice. Applied Clinical Trials. June 26, 2026. Accessed August 12, 2026. https://www.appliedclinicaltrialsonline.com/view/applied-clinical-trials-2026-dia-global-annual-meeting-data-outsourcing-patient-voice